The Avingtrans nuclear fundraise of £21m drove the engineer to the top of AIM’s risers on Thursday, with Impax Asset Management and Genedrive also climbing on positive news.
Avingtrans Nuclear Fundraise Targets £90m Revenue
Avingtrans (AVG) placed 3,309,000 new ordinary shares at 630p each, matching the previous day’s closing price, to raise approximately £21m, according to Yahoo Finance. The funds will finance expansion at its Michigan nuclear facility.
Annual nuclear revenues currently stand at around £35m. The group is targeting approximately £90m by 2031, implying an addition of roughly £55m, with EBITDA potentially rising by between £9.6m and £45m.
The Michigan investment will cover new production equipment, workforce growth, and additional working capital. The group’s nuclear work spans new-build projects, plant life extension, decommissioning programmes, and fusion energy applications. A £5m contingency built into the raise could also be deployed elsewhere in the business.
The share price rose 4.76% to 660p.
AIM Risers: Impax, Genedrive, Thruvision
Impax Asset Management (IPX) gained 15.7% to 109.9p after third-quarter assets under management came in 4.45% above the prior quarter at £23.3bn. Cavendish lifted its full-year AUM forecast by 12% to £23.3bn and raised its pre-tax profit estimate 7% to £22.2m. The broker’s forecast for the following year jumped 285% to £24.1m.
Genedrive (GDR) rose 10.2% to 1.35p after the UK government highlighted personalised medicine at a parliamentary event on 10 July 2026, specifically ‘identifying newborn babies at risk of antibiotic-induced hearing loss’, as reported by Share Talk.
The company’s MT-RNR1 ID Kit, developed with Manchester University NHS Foundation Trust, screens newborns for a genetic mutation that causes ototoxicity, enabling treatment decisions within actionable timeframes. The FT Markets regulatory announcement from Genedrive’s 10 July filing confirmed the kit helps prevent antibiotic-induced hearing loss in newborns.
The kit has been deployed across NHS settings, with Genedrive confirming its first NHS deployments, and has since been rolled out nationally in Scotland following introduction by NHS Greater Glasgow and Clyde, per a Genedrive announcement on the Scotland roll-out. The National Institute for Health and Care Excellence published an early value assessment of the kit in March 2023, available via NICE.
Thruvision (THRU) added 3.7% to 0.7p. The UK government’s National Protective Security Authority tested its 8108 WalkTHRU screening system and found it capable of ‘screening non-divested individuals for mass casualty threats’.
AIM Fallers
Sancus Lending (LEND) dropped 8.33% to 1.1p. The company appointed Andrew Charnley, who previously ran its UK subsidiary, as chief executive. Former chief executive Rory Mepham moves to a role at majority shareholder Somerston Group. The political and economic backdrop has weighed on activity levels and profitability, though efficiency improvements could return the business to profit in the second half.
Forgent (FORG) fell 6.25% to 0.015p after circularising shareholders to approve a pivot to ‘the acquisition, exploration and development of critical and precious metals projects, primarily in Australia’. A general meeting is scheduled for 6 August.
Clean Power Hydrogen (CPH2) dipped 1.82% to 1.35p. Shareholder Joe Scott Mouldings was diluted from 7.86% to 5.78% following a recent fundraising; Aurelius Ltd’s stake fell from 4.17% to 3.69%.
Chariot Ltd (CHAR) slipped 0.49% to 1.5275p. The company filed notice of its AGM, to be held on 22 September, including a resolution proposing a 25-for-one share consolidation, per the LSE RNS filing. Chariot is divesting renewable assets and pursuing further oil and gas revenues; a transaction involving offshore assets in Angola is expected to complete shortly. The stock launched at 145p, highlighting the scale of the decline since float.
